Sarepta Charges Ahead With DMD Gene Therapy Despite Setback

Company Announces Q4 2021 Results

 
• By Alaric DeArment

The company plans to start its Phase III trial of SRP-9001 in the middle of this year, with a potential readout by the end of 2022.

4th quarter computer key on key board
Sarepta talked about plans for its gene therapy for DMD on its 4Q and full-year 2020 earnings call. • Source: Shutterstock

More from R&D

More from Scrip